Bristol Myers Squibb (BMY) income statement
NYSE · Healthcare · Drug Manufacturers - General · 32,500 employees · CEO Christopher Boerner
- Price
- $62.48 +1.78%
- Market cap
- $128B
- Enterprise value
- $163B
- Last report
- Q3 '26 filed 2026-10-29
- Next report
- 2027-02-04 EPS est. $1.52
Bristol Myers Squibb (BMY) reported revenue of $13.1B for Q3 '26 (+6.9% year on year), operating income of $2.84B (21.8% of revenue) and net income of $2.16B. Over the last four quarters revenue was $50B.
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.5B | $11.9B | $12.2B | $11.9B | $12.3B | $11.2B | $12.3B | $12.2B | $12.5B | $11.5B | $13B | $13.1B | |
| Cost of revenue | $2.75B | $2.93B | $3.27B | $2.96B | $4.81B | $3.03B | $3.37B | $3.44B | $4.1B | $3.42B | $3.73B | $4.15B | |
| Gross profit | $8.73B | $8.93B | $8.93B | $8.94B | $7.53B | $8.17B | $8.9B | $8.79B | $8.41B | $8.07B | $9.25B | $8.92B | |
| Research & development | $2.48B | $2.7B | $2.9B | $2.37B | $3.19B | $2.26B | $2.58B | $2.53B | $2.59B | $2.65B | $2.96B | $2.37B | |
| Sales & marketing | $0 | $2.37B | $0 | $1.98B | $0 | $1.58B | $0 | $0 | $0 | $0 | $0 | $0 | |
| General & administrative | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.83B | $1.7B | |
| Other operating expenses | $2.28B | $2.36B | $2.42B | $2.41B | $1.69B | $830M | $830M | $831M | $826M | $437M | $437M | $2.02B | |
| Operating expenses | $6.83B | $7.42B | $7.24B | $6.76B | $7.02B | $4.67B | $5.12B | $5.15B | $5.59B | $4.7B | $5.22B | $6.08B | |
| Operating income | $1.9B | $1.51B | $1.69B | $2.17B | $510M | $3.5B | $3.77B | $3.64B | $2.81B | $3.37B | $4.03B | $2.84B | |
| Interest income | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $101M | $0 | |
| Interest expense | $316M | $425M | $521M | $505M | $496M | $494M | $485M | $480M | $432M | $411M | $407M | $403M | |
| Other non-operating income (gains on investments, FX ...) | -$87M | $12.6B | -$116M | -$9M | -$161M | $32M | $1.52B | $45M | $911M | -$286M | -$468M | -$96M | |
| Total non-operating income | -$229M | -$13B | -$405M | -$496M | -$335M | -$526M | -$2B | -$525M | -$1.34B | -$125M | $61M | -$307M | |
| Income before tax | $1.67B | -$11.5B | $1.29B | $1.68B | $175M | $2.97B | $1.77B | $3.11B | $1.47B | $3.24B | $4.09B | $2.54B | |
| Income tax | -$88M | $392M | -$398M | $461M | $99M | $509M | $460M | $919M | $384M | $561M | $770M | $374M | |
| Net income | $1.76B | -$11.9B | $1.68B | $1.21B | $72M | $2.46B | $1.31B | $2.2B | $1.09B | $2.68B | $3.32B | $2.16B | |
| EPS (basic) | $0.87 | -$5.89 | $0.83 | $0.60 | $0.04 | $1.21 | $0.64 | $1.08 | $0.53 | $1.31 | $1.62 | $1.06 | |
| EPS (diluted) | $0.87 | -$5.89 | $0.83 | $0.60 | $0.04 | $1.20 | $0.64 | $1.08 | $0.53 | $1.31 | $1.62 | $1.05 | |
| Shares (basic, weighted) | 2.03B | 2.02B | 2.03B | 2.03B | 2.03B | 2.03B | 2.04B | 2.04B | 2.04B | 2.04B | 2.04B | 2.04B | |
| Shares (diluted, weighted) | 2.03B | 2.02B | 2.03B | 2.03B | 2.04B | 2.04B | 2.04B | 2.04B | 2.04B | 2.04B | 2.05B | 2.05B | |
| Depreciation & amortization | $2.46B | $2.53B | $2.6B | $2.59B | $1.88B | $1.01B | $1.01B | $1.01B | $977M | $594M | $594M | $0 | |
| EBITDA | $4.45B | -$8.56B | $4.4B | $4.77B | $2.55B | $4.48B | $3.27B | $4.61B | $2.88B | $4.25B | $5.09B | $2.94B |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.4B | $20.8B | $22.6B | $26.1B | $42.5B | $46.4B | $46.2B | $45B | $48.3B | $48.2B | |
| Cost of revenue | $4.97B | $6.01B | $6.47B | $8.08B | $11.8B | $9.94B | $10.1B | $10.7B | $14B | $13.9B | |
| Gross profit | $14.5B | $14.8B | $16.1B | $18.1B | $30.7B | $36.4B | $36B | $34.3B | $34.3B | $34.3B | |
| Research & development | $5.01B | $6.47B | $6.33B | $6.15B | $11.1B | $10.2B | $9.51B | $9.3B | $11.2B | $9.95B | |
| Sales & marketing | $4.98B | $4.75B | $4.55B | $4.87B | $7.66B | $7.69B | $7.81B | $0 | $0 | $0 | |
| General & administrative | $91M | $162M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Other operating expenses | $0 | $97M | $97M | $1.14B | $9.76B | $10B | $9.6B | $9.05B | $8.87B | $3.32B | |
| Operating expenses | $9.99B | $11.3B | $11B | $12.2B | $28.6B | $27.9B | $26.9B | $26.1B | $28.4B | $20.5B | |
| Operating income | $4.47B | $3.45B | $5.11B | $5.91B | $2.18B | $8.54B | $9.1B | $8.2B | $5.89B | $13.7B | |
| Interest expense | $167M | $196M | $183M | $656M | $1.42B | $1.33B | $1.23B | $1.17B | $1.95B | $1.89B | |
| Other non-operating income (gains on investments, FX ...) | -$1.62B | -$1.88B | -$1.04B | $282M | $7.63B | -$895M | $159M | -$1.41B | $12.3B | $2.51B | |
| Total non-operating income | $1.45B | $1.69B | $854M | -$938M | -$9.05B | -$439M | -$1.39B | $245M | -$14.3B | -$4.4B | |
| Income before tax | $5.92B | $5.13B | $5.97B | $4.98B | -$6.87B | $8.1B | $7.71B | $8.44B | -$8.38B | $9.33B | |
| Income tax | $1.41B | $4.16B | $1.02B | $1.52B | $2.12B | $1.08B | $1.37B | $400M | $554M | $2.27B | |
| Net income | $4.46B | $1.01B | $4.92B | $3.44B | -$9.02B | $6.99B | $6.33B | $8.03B | -$8.95B | $7.05B | |
| EPS (basic) | $2.67 | $0.61 | $3.03 | $2.02 | -$3.98 | $3.15 | $2.97 | $3.88 | -$4.41 | $3.46 | |
| EPS (diluted) | $2.65 | $0.61 | $3.03 | $2.01 | -$3.98 | $3.12 | $2.95 | $3.86 | -$4.41 | $3.45 | |
| Shares (basic, weighted) | 1.67B | 1.65B | 1.63B | 1.71B | 2.26B | 2.22B | 2.13B | 2.07B | 2.03B | 2.04B | |
| Shares (diluted, weighted) | 1.68B | 1.65B | 1.64B | 1.71B | 2.26B | 2.25B | 2.15B | 2.08B | 2.03B | 2.04B | |
| Depreciation & amortization | $382M | $789M | $637M | $1.75B | $10.4B | $10.7B | $10.3B | $9.76B | $9.6B | $4.01B | |
| EBITDA | $6.46B | $6.12B | $6.79B | $7.38B | $4.93B | $20.1B | $19.2B | $19.4B | $3.17B | $15.2B |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data as of 2026-11-01